Key Takeaways
- B2C missed its 18-20% target, landing at 14%: delayed product launches from political and geographical issues pushed revenue into FY27, while a higher B2B share diluted the mix. The launches are delayed, not cancelled, and are expected to go live in the next one to two months.
- Consolidated margins dipped on deliberate R&D investment: roughly INR 3-4 crores spent on niche molecules and bioequivalence studies dragged margins, but these same studies unlock less-competitive markets like Chile and Mexico, promising better margins once commercialized.
- Inventory and cash flow are tied to the US RLD distribution cycle: the sharp inventory build and weak consolidated operating cash flow of INR 18 crores reflect the Espee Global model of holding stock for large customer orders, with funds invested in March returning in April/May.
- The product pipeline is broadening fast into GLP-1, biosimilars and specialty CNS: semaglutide filings, in-licensed Peg-filgrastim, and a new clinical trial services subsidiary signal a deliberate move up the value chain beyond the legacy anti-infective base.
- What to watch next quarter: whether the delayed Q4 launches actually convert into the promised Q1 bump-up, the pace of B2C’s climb toward the 30% target, and any early revenue contribution from the new Espee Global Clinical Trial Services subsidiary.
B2C Trajectory and the Launch-Delay Miss
- The 4-point gap: B2C contribution reached 14% against an 18-20% target, with delayed product launches as the primary driver; a higher B2B share of total revenue further diluted the B2C percentage.
- Launches delayed, not lost: the products held back by political and geographical issues are expected to be up and running in the next one to two months, giving a bump-up in Q1 FY27.
- FY27 ambition reset higher: management is now targeting at least 30% of total revenue from B2C, with double growth on the B2C segment, while B2B topline is guided to grow 25-30%.
Arpit Shah: "So, to contribute to the gap of 4%, to put it in that way, that were our expectations from the last year's growth on the B2C. Second is, we are comparing this with the total revenue. So, on our B2B, we've increased our share of sales a little. So, that also would give us a slightly lower on the B2C. What has changed for now is, the launch was delayed. It was not cancelled."
Margin Structure and the R&D Bet
- Standalone vs consolidated split: standalone PAT margins sit at 27%, while consolidated margins are lower because the US subsidiary Espee Global is a high-volume, lower-margin distributor of reference-listed innovative products and RLDs.
- The R&D drag: INR 3-4 crores invested in niche new molecules and bioequivalence studies pulled consolidated margins down in FY26, but these studies are the entry ticket to markets like Chile and Mexico where human clinical trial requirements thin out the competition.
- New subsidiary overhead: subsidiaries incorporated in the past two years are not yet 100% operational, so their operational expenses weigh on consolidated margins without contributing proportional revenue.
- Margin recovery path: standalone PAT margins are expected to improve as B2C scales from 14-15% to 30% of the business; consolidated margins should lift as Algeria, Mexico, and Chile become revenue runners over the next 1 to 1.5 years with less competition and better pricing.
Arpit Shah: "So, that is an access to the markets like Chile or Mexico, which I can brief you on it that these are the markets need bioequivalence studies and any product bioequivalence study is not that cheap. So, we have already filing in this market and for us, we will be having less competitors and of course, if we are having human clinical trials on that, we will have a better margin than not having the products with clinical trials."
Working Capital and the US Distribution Model
- Inventory build is cyclical, not structural: the sharp increase in FY26 inventories stems from the US RLD distribution business, where the company holds stock for customers placing million-dollar orders and ships in parts aligned to their study timelines; funds deployed in March return in April/May.
- Cash flow split tells the story: consolidated operating cash flow of INR 18 crores is weighed down by the inventory-holding requirement of the US model, while standalone operating cash flow is INR 25 crores with comparatively lower working capital allocation.
- Debtor days edged up on geopolitics: the increase came from geopolitical disruption in the last month of the financial year, and management expects a reduction as the company expands into new regions.
- Chronic product planning provides visibility: the company plans six months ahead for chronic and fast-moving products, maintaining 2-3 years of shelf life, with the next six months of dispatches from India already planned.
Pipeline Expansion: GLP-1, Biosimilars and Clinical Trial Services
- Semaglutide entry: filings initiated for both tablets and injections across non-patented emerging markets through B2B and B2C channels, marking entry into the GLP-1 and anti-obesity segment; commercialization planned in 3-4 non-patented countries this year, with patent-expiry readiness for markets where patents run to 2027-2029.
- Biosimilar in-licensing: Peg-filgrastim and Filgrastim PFS injection in-licensed for Philippines and Vietnam, manufactured in the US; regulatory submissions are being filed step-by-step given the cumbersome process for biological products.
- Espee Global Clinical Trial Services: a new subsidiary expected to become operational anytime this year, functioning as a service distribution arm that will partially add to margins this year and fully from next year.
- Pegfilgrastim pricing model: government buyers in target markets prefer US-approved products even at a 2x price premium, which management sees as a beneficial model balanced by higher-margin B2C sales.
Arpit Shah: "The government buys at a much cheaper cost than in the U.S. And always the government has this preference that they will buy a product which is U.S. approved even at a 2x price. So, that will also be a beneficial model for us."
Geographical and Therapeutic Expansion
- Four new markets added: commercial presence expanded into Myanmar, Nicaragua, Macedonia, and Madagascar.
- Latin America deepening: in-licensed Rifaximin and Fexofenadine for Mexico, Chile, and Peru; launched Mirabegron and Mirabegron plus Solifenacin across four Latin American countries; filed five products with Chile ISP and three SKUs of Rivaroxaban with bioequivalence studies.
- Bolivia B2C ramp: through Relius Bolivia subsidiary, 26 products launched under B2C with an additional 40 products planned in the next two to three months; the company operates both B2B and B2C in Bolivia through its subsidiaries.
- Peru acceleration: 60 products planned to be filed in three months, with faster approval time and commercialization expected in this financial year itself, reinforced by a successfully cleared DIGEMID audit in February 2026.
- CNS and specialty build-out: launched Brivaracetam, Valproic acid, Risperidone, and Lamotrigine tablets; executed direct supply orders for Rivastigmine patches in Venezuela; registered Triptorelin injection in Bolivia for government and private markets.
- Tender wins adding recurrence: secured Nicaragua government tender for ceftazidime Avibactam, expected to recur every quarter or two; secured Saudi Arabia NUPCO tender for Topiramate capsules; secured North Macedonia anti-TB tender for a four-drug fixed-dose combination supplied from an EU GMP-approved plant.
Business Model Defense
- Not trading, but registration-heavy: management pushed back on the "trading" label by pointing to gross margins of 55-60%, which reflect investments in product registration timelines of six months to three years, brand building, marketing, and regulatory dossiers of 1,000-5,000 pages per product.
- Asset-light by design: the company deliberately avoids owning manufacturing sites, citing the example of Eris which reached a INR 10,000 crore market cap at IPO without a single plant; 34 approved manufacturers are in the network, with roughly 20 active, each vetted through a licensing sourcing team that spends 2-4 days on-site checking infrastructure and QC/QA before regulatory verification.
- Specialized and chronic focus: the portfolio targets specialized and chronic products, not me-too generics, which supports the margin profile and competitive positioning.
Arpit Shah: "If this was a trading business, my gross margin wouldn't have been anywhere between 55% to 60%. This is a very organized business model that we have been doing where the products are registered. The registration is not a week or two weeks or four weeks' timeline. The registration is between six months to two years or three years."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| B2C revenue share | At least 30% of total revenue from B2C, with double growth on B2C | FY27 |
| B2B topline growth | 25-30% growth from revenue perspective | FY27 |
| Delayed launch conversion | Launches delayed from Q4 to give a bump-up | Q1 FY27 |
| Bolivia B2C launches | Additional 40 products launched | Next 2-3 months |
| Peru product filings | 60 products filed, with commercialization | This financial year |
| Semaglutide commercialization | Launch in 3-4 non-patented countries where filings are done | This year |
| Margin improvement | Standalone PAT margins to improve as B2C scales to 30%; consolidated margins to lift as Algeria, Mexico, Chile become revenue runners | Next 1-1.5 years |
| Espee Global Clinical Trial Services | Operational, partially adding to margins this year, fully from next year | Anytime this year |
| Nicaragua tender recurrence | Ceftazidime Avibactam order expected every quarter or two | Ongoing |
| Debtor days | Reduction expected as company moves to new regions | Undated |
Key Metrics
| Metric | FY26 / H2 FY26 |
|---|---|
| Consolidated revenue (FY26) | ₹854 cr, 38% YoY growth |
| Consolidated revenue (H2 FY26) | ₹453 cr, 30% YoY growth |
| Standalone revenue (H2 FY26) | ₹47 cr, 14% YoY growth |
| Consolidated EBITDA (FY26) | ₹57 cr, 24% YoY growth |
| Consolidated EBITDA margin (H2 FY26) | 6.57% |
| Standalone EBITDA margin (H2 FY26) | 31.85% |
| Consolidated net profit (FY26) | ₹46 cr, 20% YoY growth |
| Net profit attributable to holding company (FY26) | ₹37 cr, 27% YoY growth |
| Standalone PAT margin (H2 FY26) | 26.96% |
| B2C revenue contribution | 14% of total revenue, up from 4% last year |
| B2B revenue contribution | 86% of total revenue |
| B2C growth target (FY27) | at least 30% from total revenue perspective |
| B2B growth target (FY27) | 25%–30% from revenue perspective |
| R&D investment (FY26) | ~₹3–4 cr, impacting consolidated margins |
| Consolidated operating cash flow (FY26) | ~₹18 cr |
| Standalone operating cash flow (FY26) | ~₹25 cr |
| Gross margin (finished formulations business) | 55%–60% |
| Countries of operation | 40+ countries for export of finished formulations |
| Products launched in Bolivia (B2C) | 26 products launched, 40 additional planned in next 2–3 months |
| Products planned for filing in Peru | 60 products in three months |
| Brand names and trademarks registered for B2C | 126 |
| Active manufacturing partners | ~20 actively, 34 approved |
| Shipment mode | 30%–35% by sea, rest by air |
| Advance payment range | 25%–50% in most cases |
| Inventory buffer for chronic products | 4–5 months minimum, not exceeding 6 months |